skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

The MCF7/182R-1 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal anti-oestrogen ICI 182,780 (Fulvestrant) in 100 nM concentration, Lykkesfeldt et al (1995).The MCF7/182R-1 cells can be maintained continuously in growth medium with 100 nM fulvestrant.

Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.

General Info


Human (Homo sapiens)

Unique to ECACC


Also Known As


Release Conditions

Restricted - all organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.



Oestrogen receptor only. Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level. The MCF7/182R-1 cells do not express progesterone receptor.

Tissue of Origin



Polygonal epithelium

DNA profile (STR Profile)

Amelogenin: X, X
CSF1PO: 10,10
D3S1358: 16, 16
D5S818: 11,12
D7S820: 9,9
D8S1179: 10,14
D13S317: 11,11
D16S539: 11,12
D18S51: 14, 14
FGA: 23, 25
Penta D: 7,12
Penta E: 12,12
TH01: 6,6
TPOX: 9,12
vWA: 14, 15


Treatment with the steroidal anti-oestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. This cell line will provide a model for the clarification of molecular changes associated with the development of resistant growth after targeted treatments.



Culture Conditions

Cell Type


Subculture Routine

Split sub-confluent cultures at 70-80% confluency. Subculture cells using 0.05% trypsin/EDTA solution and soya bean trypsin inhibitor or TrypLE Express™ (1X), without phenol red, and wash with phosphate-buffered saline (PBS). Pellet cells by centrifugation and re-suspend in growth medium.

Initiate the culture at a dilution of approximately 1:3 to 1:6 i.e. seeding at 2-4 x 104 cells per cm2. Incubate cultures in 5% CO2 in air at 37°C. Recommend media changes every 2-3 days per cm2.

Cells can be cryopreserved in either a mixture of cell line conditioned medium (45%) and fresh serum free-medium (45%) with 10% dimethyl sulphoxide (DMSO) or 90% Foetal Bovine Serum (FBS) and 10% dimethyl sulphoxide (DMSO). It is recommended that upon resuscitation the cells are washed in phosphate- buffered saline (PBS) or serum-free medium, pelleted by centrifugation and re-suspended in growth medium prior to initiation of culture.

Culture Medium

Phenol red free DMEM/F12 (1:1) supplemented with 1% FBS, Glutamax 2.5 mM and 6 ng/ml insulin.

Supplemented with 100nM fulvestrant to maintain resistance.

Growth Mode


Additional Info


Cancertools (formally Ximbio) 2 Redman Place, London E20. 1JQ Tel +44 (0) 20 3469 6449 Originator: Anne Lykkesfeldt, Breast Cancer Research Department, Danish Cancer Society, Copenhagen.

Country of Origin


GMO Status

Not Applicable

Hazard Group (ACDP)

Hazard Group (ACDP) 2



Frogne et al. 2005. Endocr.Relat.Cancer. 12(3):599-614. PMID: 16172194.
Christensen et al. 2004. Breast Cancer Res.Treat. 85(1):53-63. PMID: 15039597.
Larsen et al. 1997. Int J. Cancer. 72(6):1129-36. PMID: 9378550.
Lykkesfeldt et al. 1995. Int J. Cancer. 61(4):529-34. PMID: 7759159.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/182R-1 (ECACC 16022529).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.


ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.